Know Cancer

forgot password

Phae I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER) as Salvage Therapy With Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients in First Relapse

Phase 1/Phase 2
18 Years
Open (Enrolling)
Diffuse Large B-cell Lymphoma.

Thank you

Trial Information

Phae I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER) as Salvage Therapy With Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients in First Relapse

This is a 3-Stage, phase I/II, single-arm, open-label study. The first and second stage of
the study will assess the safety and efficacy of lenalidomide, rituximab, Ifosfamide,
etoposide, and carboplatin (RICER) for the treatment of DLBCL patients in first relapse.
The third stage of the study will assess the safety and efficacy of post-ASCT lenalidomide
maintenance in patients with DLBC.

In stage I of the study, escalating doses of lenalidomide (10, 15, 20, and 25 mg daily x 7
days on Days 1-7) along with RICE therapy will be given to cohorts of subjects in a standard
3+3 design (see section 5.4.2 for dose escalation schema) until the maximum tolerated dose
(MTD) has been determined.

In stage II, all subjects will be given RICE plus the MTD of lenalidomide. The starting
dose of lenalidomide in Stage II will be modified for reduced renal function as outlined in
Section 5.4.2.

In both stage I and stage II, subjects who have stable disease or progression of disease
after 2 cycles of RICER will be taken off study. Subjects who achieve > PR to 2 cycles of
RICER will receive a third cycle followed by stem cell collection and ASCT.

Each cycle is 14 days. Delays in initiating a new cycle are allowed up to 14 days for Stages
I and II. The planned number of cycles is 3.

After the second cycle, restaging with PET and CT scans is performed. Patients with
progressive disease are removed from the study, chemosensitive patients (CR/Cru and PR)
proceed with third cycle of RICER. Stem cell collection will be completed within 10-14 days
after third cycle of RICER. HDCMT-autoSCT will be performed after patient recovers from stem
cell collection toxicities. HDCMT (high dose chemotherapy) followed by autologous stem cell
transplant involves administration of chemotherapy with BEAM (BCNU, Etoposide, Ara-C,
Melphalan) followed by infusion of autologous stem cells. Involved-field radiation to the
sites of bulky disease will be allowed prior to HDCMT-SCT.

Stage III, after recovery from aSCT, but not to exceed 90 days all eligible subjects will
receive lenalidomide maintenance therapy (po daily on Days 1-21 q28 days) for up to 1 year.
Delays in initiating a new cycle up to 28 days are allowed in Stage III. Subjects will be
followed for progression- free survival and overall survival for up to 2 years. The
starting dose of lenalidomide maintenance treatment will be based on calculated creatinine
clearance within 28 days prior to the start of lenalidomide maintenance

Inclusion Criteria:

Understand and voluntarily sign an informed consent form.

1. Age 18 years at the time of signing the informed consent form.

2. Able to adhere to the study visit schedule and other protocol requirements.

3. Histologically confirmed diffuse large B cell lymphoma

4. Relapsed or refractory after one prior therapeutic treatment for DLBCL. Refractory is
defined as patients received adequate prior treatment and did not respond during
treatment or progressed within 90 days of last treatment.

5. Measurable disease with at least on bidimensional lymph node or tumor mass >1.5 cm in
the longest diameter that can be followed for response as a target lesion as measured
by PET or CT

6. Histologically confirmed involvement of the bone marrow by DLBCL on the bone marrow
biopsy without other measurable disease

7. Eligible for autologous stem cell transplant

8. All previous cancer therapy, including radiation, hormonal therapy and surgery, must
have been discontinued at least two weeks prior to treatment in this study.

9. ECOG performance status of 2 at study entry (see Appendix B).

10. Laboratory test results within these ranges:

- Absolute neutrophil count >1000 /mm³

- Platelet count > 50,000/mm³ (unless bone marrow is heavily infiltrated with
underlying disease (50% or more) Calculated creatinine clearance of ≥ 60 mL/min
by Cockroft-Gault formula (Appendix E) for patients enrolled into the phase I
portion of the study (Stage I). Calculated creatinine clearance of ≥ 30 mL/min
by Cockroft-Gault formula for patients enrolled into the phase II portion of the
study (Stage II). See Section 5.4.2 for lenalidomide dose adjustment for
calculated creatinine clearance > 30ml/min and < 60ml/min.

- Total bilirubin < 1.5 x ULN.

- AST (SGOT) and ALT (SGPT) < 3 x ULN.

11. Disease free of prior malignancies for > 5 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix
or breast.

12. All study participants must be registered into the mandatory RevAssist® program, and
be willing and able to comply with the requirements of RevAssist®.

13. Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
and again within 24 hours of starting lenalidomide and must either commit to
continued abstinence from heterosexual intercourse or begin TWO acceptable methods of
birth control, one highly effective method and one additional effective method AT THE
SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also
agree to ongoing pregnancy testing. Men must agree to use a latex condom during
sexual contact with a FCBP even if they have had a successful vasectomy. All
patients must be counseled at a minimum of every 28 days about pregnancy precautions
and risks of fetal exposure. See Appendix A: Risks of Fetal Exposure, Pregnancy
Testing Guidelines and Acceptable Birth Control Methods.

14. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
intolerant to ASA may use warfarin or low molecular weight heparin).


Exclusion Criteria: Any serious medical condition, laboratory abnormality, or psychiatric
illness that would prevent the subject from signing the informed consent form.

1. Pregnant or breast feeding females. (Lactating females must agree not to breast feed
while taking lenalidomide).

2. Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study.

3. Evidence of laboratory TLS by Cairo-Bishop Definition of Tumor Lysis Syndrome.
Subjects may be enrolled upon correction of electrolyte abnormalities.

4. Use of any other experimental drug or therapy within 28 days of baseline.

5. Known hypersensitivity to thalidomide.

6. The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide or similar drugs.

7. Concurrent use of other nonprotocol anti-cancer agents or treatments.

8. Known positive for HIV or active infectious hepatitis, type B or C.

9. Refusal of autologous stem cell transplant.

10. Patients with active central nervous system involvement based on clinical evaluation.
Previously treated CNS involvement that has remained asymptomatic for more than
ninety days is allowed if no active CNS disease present as confirmed by MRI or/and
lumbar puncture.

11. Concurrent uncontrolled serious medical ort psychiatric conditions likely to
interfere with participation in this clinical study, as judged by investigator.

12. Prior Lenalidomide exposure for more than 28 days.


Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Stage 1 - Safety (type, frequency, severity and relationship of adverse events to study treatment) and tolerability

Outcome Description:

compare the effect of treatment with 4 weeks of high dose IFN α-2b on the relapse free survival of patients with resected melanoma

Outcome Time Frame:

overall response rate

Safety Issue:


Principal Investigator

Tatyana Feldman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hackensack University Medical Center


United States: Food and Drug Administration

Study ID:




Start Date:

June 2010

Completion Date:

October 2013

Related Keywords:

  • Diffuse Large B-Cell Lymphoma.
  • Diffuse Large B cell Lymphoma
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse



Duke University Medical CenterDurham, North Carolina  27710
John Theurer Cancer Center at Hackensack University Medical CenterHackensack, New Jersey  07601